177Lu-DTPA-Omburtamab (177Lu-Burtomab) is a monoclonal murine antibody, targeted against the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3 / CD276), labeled with 177Lu for the therapy of neuroblastomas, developed at MSKCC, New York, which licensed the drug exclusively to Y-mAbs Therapeutics, Inc. 177Lu-DTPA-Omburtamab is the next generation drug alternative to 131I-Omburtamab. The first patient was injected in June 2021 and the study is expected to be completed by end of 2024.